Humana (HUM) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Humana reported $32.65 billion in revenue for Q3 2025, an 11.4% year-over-year increase, with an EPS of $3.24 compared to $4.16 a year ago, indicating a decline in earnings per share [1] - The revenue exceeded the Zacks Consensus Estimate of $31.98 billion by 2.09%, and the EPS surpassed the consensus estimate of $2.91 by 11.34% [1] Financial Performance Metrics - Benefits Expense Ratio was reported at 91.1%, slightly above the average estimate of 90.9% [4] - Medical Membership in Medicare stand-alone PDP was 2.45 million, slightly below the estimated 2.46 million [4] - Medical Membership for State-based contracts and others was 1.66 million, slightly above the estimate of 1.65 million [4] - Group Medicare Advantage Medical Membership reached 569.8 thousand, exceeding the estimate of 558.84 thousand [4] - Investment income was reported at $338 million, surpassing the estimate of $271.05 million, but reflecting a -1.5% change year-over-year [4] - Premium revenues were $30.71 billion, above the estimate of $30.35 billion, showing a +9.9% change year-over-year [4] - Service revenues were $1.6 billion, exceeding the average estimate of $1.39 billion, representing a +45.1% year-over-year change [4] - Military services and other insurance segment revenues were $267 million, above the estimate of $222.94 million, with a +24.8% year-over-year change [4] - CenterWell segment revenue was $5.88 billion, exceeding the estimate of $5.49 billion, reflecting a +16.6% year-over-year change [4] - Total services revenue for CenterWell segment was $1.33 billion, surpassing the estimate of $1.17 billion, indicating a +52% year-over-year change [4] - Pharmacy solutions revenue within CenterWell segment was $352 million, slightly above the estimate of $349.81 million [4] Stock Performance - Humana's shares have returned -4.5% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]